Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum-Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

Goshi Nishimura; Hiromitsu Hatakeyama; Osamu Shiono; Masataka Taguri; Masanori Komatsu; Daisuke Sano; Naoko Sakuma; Kenichiro Yabuki; Yasuhiro Arai; Kunihiko Shibata; Yoshihiro Chiba; Teruhiko Tanabe; Nobuhiko Oridate

doi:10.2196/11003

Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum-Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial

JMIR Res Protoc. 2018 Aug 23;7(8):e11003. doi: 10.2196/11003.

Affiliations

¹ Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine, Yokohama City University, Yokohama, Japan.
² Department of Otorhinolaryngology, Yokohama City University Medical Center, Yokohama, Japan.
³ Department of Otorhinolaryngology, Yokohama Rosai Hospital, Yokohama, Japan.
⁴ Department of Data Science, School of Data Science, Yokohama City University, Yokohama, Japan.

PMID: 30139721
PMCID: PMC6127497
DOI: 10.2196/11003

Abstract

Background: We confirmed the safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel in a small number of patients with cis-platinum-intolerant core high-risk head and neck cancer.

Objective: To assess treatment efficacy, we planned a phase 2 study of postoperative bio-chemoradiotherapy for patients with cis-platinum-intolerant core high-risk head and neck cancer and will compare the results to those of previously collected radiotherapy data.

Methods: Patients who underwent definitive surgery for oral cavity, laryngeal, oropharyngeal, or hypopharyngeal advanced cancer, whose postoperative pathological results indicated core high risk for recurrence (eg, positive margin in the primary site or extranodal extension) and who were cis-platinum-intolerant, will undergo postoperative bio-chemoradiotherapy. The primary end point is 2-year disease-free survival.

Results: The expected 2-year disease-free survival is set at 55%, and the calculated sample size is 35 patients, according to a statistical analysis based on previous reports.

Conclusions: This treatment method is expected to improve the survival rate of patients with severe head and neck cancer.

Trial registration: UMIN Clinical Trials Registry UMIN000031835; https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ ctr_view.cgi?recptno=R000036355 (Archived by WebCite at http://www.webcitation.org/71fejVjMr).

Keywords: cetuximab; cis-platinum intolerant; core high-risk head and neck cancer; docetaxel; postoperative bio-chemoradiotherapy.

©Goshi Nishimura, Hiromitsu Hatakeyama, Osamu Shiono, Masataka Taguri, Masanori Komatsu, Daisuke Sano, Naoko Sakuma, Kenichiro Yabuki, Yasuhiro Arai, Kunihiko Shibata, Yoshihiro Chiba, Teruhiko Tanabe, Nobuhiko Oridate. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 23.08.2018.